跳至主要内容
临床试验/NCT04349293
NCT04349293Unknown不适用

Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways

Gustave Roussy, Cancer Campus, Grand Paris2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2016年9月8日最近更新:
适应症

试验速览

阶段
不适用
入组人数
150
试验地点
2
主要终点
Immunophenotyping of immune infiltrates by flow cytometry

研究概览

简要总结

Multicentric interventional prospective study with collection of biological samples as part of a routine care research

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater than or equal to 18 years.
  • Male and female sex.
  • Any patient with cancer (see list in the body of the protocol) requiring treatment by surgical resection and / or who will start treatment with mAb or BiTE.
  • Patient information and signed informed consent.
  • Subjects affiliated (or beneficiary) to a social security scheme
  • Patients treated for immune complications by immunosuppressants may be included (corticosteroids, etc.).

排除标准

  • History of severe systemic autoimmune disease.
  • Pregnant or breastfeeding patient
  • Impossibility or refusal to sign informed consent
  • Patient under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision

结局指标

主要结局

Immunophenotyping of immune infiltrates by flow cytometry

时间窗: Up yo one year

Immunophenotyping analysis by flow cytometry (Cyan, Beckman Coulter): identification of several immune sub-populations (T-B-NK lymphocytes, myeloid and tumor cells); identifications of several receptors and ligands (PD1 / PDL1, Tim-3 / HAVCR2,, CTLA-4, 4-1BB / 4-1BBL, Fas / FasL, TRAIL, OX40 / OX40L, ICOS / ICOSL, CD69, CD25 / CD127, NKp46 / NKp30, NKG2D / NKG2DL, galectin-9, MHC class I and II, B7H3 / B7H6); identification of memory subpopulations (CD45RA / CD27 / CCR7) and, if available, intra-cytoplasmic labeling (CXCR3, CCR6, Granzyme B, KI67, TNFα IFNg, IL-17 and IL-21).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验